Several clinical studies have shown that GLP-1 receptor agonists, including semaglutide and liraglutide, and the dual GIP/GLP-1 receptor agonist tirzepatide, reduce liver steatosis and inflammation in MASLD patients [35]
Call us today at 423-212-3703 or schedule online to book your Semaglutide consultation
Other GLP-1 tablets include: Rybelsus available in the UK, but licensed for type 2 diabetes only and cannot be used for weight loss orforglipron (brand name Foundayo) was approved in the US in April 2026 after successful clinical trials, so may be available in the UK in the future from 87.97 No results found
107 (2B): S28 Dyck PJ, Zimmerman BR, Vilen TH, et al
doi: 10.2165/00003088-200342110-00002 36 PalaciosR
Financial Health & Key Metrics Lillys recent results reflect both growth and margin expansion